Influence of the @entity9667 polymorphism on vasomotor symptoms in postmenopausal XXXX : a pilot study.

@entity172 @entity1 @entity251 @entity1641 @entity9667 @entity342 @entity443
OBJECTIVE: To evaluate the influence of @entity9667 polymorphism on menopausal symptoms after @entity172 treatment. METHODS: A total of 130 @entity1 were recruited, but only 100 of these were selected according to inclusion and exclusion criteria; they were treated with 0.3 mg/day conjugated @entity1641 @entity172 . One year later, the study was completed by 71 @entity1 . The analysis of the Kupperman menopausal index symptoms was made with information provided by the @entity1 on daily diary cards. Blood samples were analyzed and the @entity1 were divided into two groups based on the @entity9667 , 5'-untranslated region: group A (wild-type homozygote and heterozygote) and group B (mutated homozygote). RESULTS: The values for the Kupperman menopausal index were similar in both groups at baseline. The symptoms in both groups decreased after 1 year of treatment when compared to those at baseline. The improvement rate was approximately 27.09% and 32.18%, in groups A and B, respectively. The levels of @entity172 after treatment were higher in both groups in comparison with the baseline values. The @entity251 level rose in group B with the 1-year treatment (0.48 + 0.16 ng/ml), reaching a higher level than the level in group A after treatment. The @entity443 ( @entity443 ) level showed a significant increase after the 1-year treatment in group B, surpassing both the baseline and the after-treatment values in group A (p < 0.01). CONCLUSION: Our data suggest that the @entity9667 polymorphism did not influence the action of @entity172 on menopause symptoms during the 1-year treatment. The extra production of @entity172 and @entity342 may have been countered by the elevation of @entity443 levels.
